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Background: Liver failure has remained a major cause of mortality after hepatectomy, but it is difficult
to predict preoperatively. This study describes the introduction into clinical practice of the new LiMAx test
and provides an algorithm for its use in the clinical management of hepatic tumours.
Methods: Patients with hepatic tumours and indications for hepatectomy were investigated periopera-
tively with the LiMAx test. In one patient, analysis of liver volume was carried out with preoperative
three-dimensional virtual resection.
Results: A total of 329 patients with hepatic tumours were evaluated for hepatectomy. Blinded preop-
erative LiMAx values were significantly higher before resection (n = 139; mean 351 mg/kg/h, range
285–451 mg/kg/h) than before refusal (n = 29; mean 299 mg/kg/h, range 223–376 mg/kg/h; P = 0.009).
In-hospital mortality rates were 38.1% (8/21 patients), 10.5% (2/19 patients) and 1.0% (1/99 patients) for
postoperative LiMAx of <80 mg/kg/h, 80–100 mg/kg/h and >100 mg/kg/h, respectively (P < 0.0001). A
decision tree was developed to avoid critical values and its prospective preoperative application revealed
a reduction in mortality from 9.4% to 3.4% (P = 0.019).
Discussion: The LiMAx test can validly determine liver function capacity and is feasible in every clinical
situation. Combination with virtual resection could enable the calculation of residual liver function. The
LiMAx decision tree algorithm for hepatectomy might significantly improve preoperative evaluation and
postoperative outcome in liver surgery.
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Introduction
Predicting postoperative hepatic dysfunction is becoming
increasingly important as surgeons pursue a more aggressive
approach to achieving complete tumour resection.1 Accordingly,
residual liver function has become the major limitation for sur-
gical treatment.2 Small residual liver volume can result in signifi-
cant problems in terms of postoperative liver function, as well as
effective liver regeneration.3,4 Postoperative liver failure (PLF)
remains a major cause of mortality after liver resection.2
Outcome and prognosis are closely associated with the occur-
rence of PLF, which is always a life-threatening complication
with high mortality.2,5 A meta-analysis estimated the overall inci-
dence of PLF after hepatectomy to lie between 0.7% and 9.1%.5
Actual mortality rates outside reported studies may be even
higher,6 reducing the overall benefit of hepatic resection and
increasing the health economic burden.7 Currently, the accurate
determination of liver function and prediction of residual liver
function represent significant challenges in perioperative patient
evaluation and monitoring.
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Conventional blood parameters of liver function, such as liver
enzymes, albumin, bilirubin or INR, as well as scoring systems
derived from those values (such as Child–Pugh or Model of End-
Stage Liver Disease [MELD] scores) have been shown to be unre-
liable for the prediction of the residual liver function.2,8,9 Similarly,
volumetric analysis of computed tomography (CT) cannot reli-
ably predict a patient’s outcome.3 Several dynamic tests for the
assessment of liver function have been developed, including non-
invasive breath tests, blood elimination tests and scintigraphy.10–12
However, there is no single test which can accurately predict
residual liver function and individual outcome. Thus, preoperative
testing to predict residual liver function has not been part of the
routine clinical management of most patients considered for
hepatic resection.
A novel test protocol, designated the LiMAx test, has been
developed at the Department of General, Visceral and Transplan-
tation Surgery at the Charité Hospital in Berlin since 2003 to
overcome these limitations. The aim of this study was to develop
a decision tree algorithm incorporating the LiMAx test for preop-
erative patient evaluation prior to hepatic resection.
Materials and methods
Patients
The clinical evaluation of the LiMAx test in perioperative moni-
toring for hepatectomy was based on 168 patients who partici-
pated in different prospective studies during 2004–2008
(Stockmann et al., 2009, unpublished data). These studies were
analogously performed in a non-controlled observational design
in accordance with the Declaration of Helsinki. Patients with
malignant hepatic tumours, who had been successfully evaluated
for hepatectomy, were asked to undergo additional perioperative
monitoring with the LiMAx test. Thus tumours of different eti-
ologies and subject to different surgical procedures were included.
The selection of patients was influenced mainly by administrative
issues and not by individual characteristics. Responsible medical
personnel were blinded to preoperative LiMAx readouts. Postop-
erative liver function was monitored until day 10. Outcome and
survival were followed until discharge from the hospital. The
study protocols received prior approval by the faculty’s ethics
committee and written informed consent was obtained from each
patient before enrolment.
In addition, a total of 161 patients were preoperatively evalu-
ated with the LiMAx test from January 2008 (Routine group). The
test was applied as an additional test during routine preoperative
patient evaluation. No regular follow-up LiMAx test after surgery
was performed. The decision for LiMAx evaluation was individu-
ally and non-systematically made by the responsible surgeons.
Thus the LiMAx test was mainly applied before critical resections
with expected small residual liver volumes or in cases of pre-
existing hepatic impairment. Written informed consent was also
collected from each of these patients.
Prospective volume and function analysis before surgery was
applied in one patient by a combination of volume planning using
virtual resection based on a conventional CT scan together with
a measurement of preoperative liver function capacity obtained
using the LiMAx test. The preoperative, multilayer, four-phase,
contrast-enhanced CT scan was transferred into specific software
for virtual three-dimensional analysis and resection (MeVis
LiverExplorer; Fraunhofer MeVis, Institute for Medical Image
Computing, Bremen, Germany). The virtual resection was per-
formed in direct cooperation with the responsible surgeon on the
day prior to hepatectomy.
Performance of the LiMAx test
The LiMAx test is based on the hepatocyte-specific metabolism of
the 13C-labelled substrate (methacetin; Euriso-top, Saint-Aubin
Cedex, France) by the cytochrome P450 1A2 enzyme, which is
ubiquitously active throughout the liver.13 After i.v. injection, the
13C-methacetin is instantly metabolized into acetaminophen and
the demethylated 13C-group is converted into 13CO2, which is pul-
monarily exhaled. Hence, the administration of 13C-methacetin
leads to a significant alteration of the normal 13CO2 : 12CO2 ratio
(Pee Dee Belemnite standard 1.1237%14) in the expired breath.
This alteration is determined by a suitable device which is directly
connected to the patient (online measurement). Breath analysis is
performed automatically. Liver function capacity is calculated
from the kinetic analysis of the 13CO2 : 12CO2 ratio over a period of
60 min. The protocol has been recently described in detail.15
LiMAx
DOB standard CO CO ratio CO production
molar m
13
2
12
2 2
=
∗ ∗ ∗max
ass C-methacetin
body weight
13( )
The resection of a certain percentage of functional liver volume
leads to an equivalent decrease in the LiMAx value after surgery.
LiMAx test readouts were highly correlated with functional liver
volume (r = 0.94; P < 0.001) and thus the LiMAx test was assumed
to represent an accurate surrogate parameter of liver function
capacity.15
Statistical analysis
Descriptive data are shown as medians with interquartile range
(IQR) unless otherwise noted. Patients were retrospectively
dichotomized into deceased and survivors to compare the pro-
gression of LiMAx values. In addition, patients were retrospec-
tively classified by their residual postoperative day 1 LiMAx values
to compare mortality rates between groups. Univariate analysis
was carried out by chi-squared test, Fisher’s exact test, Mann–
Whitney U-test, Kruskal–Wallis test or t-test in accordance with
the data scale and distribution. The level of significance was 0.05
(two-sided). The analyses were performed using spss 15.0 (SPSS,
Inc., Chicago, IL, USA).
Results
A total of 329 patients with hepatic tumours were evaluated for
hepatectomy and 59 (17.9%) were refused surgery. Forty-two
140 HPB
HPB 2010, 12, 139–146 © 2010 International Hepato-Pancreato-Biliary Association
patients (12.8%) underwent explorative laparotomy without
hepatectomy. Postoperative mortality in the 228 patients who
underwent hepatectomy was 7.0% (16 patients). The median
(IQR) length of stay was 17 days (11–30 days), including a median
(IQR) stay of 2 days (1–6 days) in intensive care. The character-
istics of patients in the two different patient cohorts are provided
in Table 1.
Study group
The clinical application of the LiMAx test began with an observa-
tional trial (Study group). Retrospective analysis revealed that
preoperative median (IQR) LiMAx values of those who underwent
hepatectomy and recovered vs. those who deceased after hepatec-
tomy were identical (354 mg/kg/h [289–458 mg/kg/h] vs. 339 mg/
kg/h [250–421 mg/kg/h]; P = 0.279). Interestingly, the overall
preoperative LiMAx values of study patients (n = 139) who under-
went surgery were significantly higher in comparison with those of
patients who were refused resection (n = 29) (Fig. 1A). Although
decisions for surgery were made independently of individual
LiMAx values, the LiMAx of refused patients was 299 mg/kg/h
(223–376 mg/kg/h) and thus below the normal range (>315 mg/
kg/h) in the majority of patients (64.3%). The LiMAx of actually
resected patients was 351 mg/kg/h (285–451 mg/kg/h) (P = 0.009)
and thus mostly within the normal range (65.5%) (Fig. 1A).
Postoperative LiMAx and functional regeneration in this cohort
revealed significantly different values between survivors and
deceased patients, as shown in Fig. 2. LiMAx values in the
deceased group were extremely low after surgery (62 mg/kg/h
[41–73 mg/kg/h] vs. 136 mg/kg/h [102–197 mg/kg/h]; P < 0.0001).
The effects of postoperatively decreased values on need for inten-
sive care, length of stay and survival are shown in Table 2.
In-hospital mortality rates were 38.1% (8/21 patients), 10.5%
(2/19 patients) and 1.0% (1/99) for LiMAx values of <80 mg/kg/h,
80–100 mg/kg/h and >100 mg/kg/h, respectively (P < 0.0001). The
cause of death for the one patient who died with a postoperative
LiMAx of 101 mg/kg/h was haemorrhagic shock secondary to an
acute peptic ulcer bleeding 4 weeks after hepatectomy from which
he developed multiple organ dysfunction syndrome.
Routine group
A total of 161 patients underwent a preoperative LiMAx as part of
their routine preoperative testing prior to consideration for
hepatic resection. The demographics and outcomes of this group
are compared with those of the Study group in Table 1. A decision
tree algorithm was developed during this period, shown in Fig. 3.
This was mainly used to evaluate patients whose histories indi-
cated a risk for hepatic injury. Eventually 72 (44.7%) of the evalu-
ated patients were excluded from hepatectomy (median [IQR]
LiMAx values of 257 mg/kg/h [175–348 mg/kg/h] vs. 356 mg/kg/h
[301–425 mg/kg/h]; P < 0.0001) (Fig. 1B). Patients who under-
went explorative laparotomy without hepatectomy (n = 23) had
median (IQR) LiMAx values of 285 mg/kg/h (239–347 mg/kg/h),
whereas those who were directly refused surgery had LiMAx
values of 240 mg/kg/h (163–369 mg/kg/h) (P = 0.159). Postopera-
Table 1 Patient characteristics
Study group Routine group P-value
2005–2008 2008–2009
Patients, n 168 161
Age, years, median (IQR) 63 (53–69) 62 (53–70) 0.835a
Male gender, n (%) 106 (63.1%) 102 (63.4%) 0.668b
Aetiology 0.005b
Colorectal metastases, n (%) 32 (19.0%) 34 (21.1%)
Hepatocellular cancer, n (%) 30 (17.8%) 46 (28.6%)
Cholangiocarcinoma, n (%) 26 (15.5%) 22 (13.7%)
Klatskin tumour, n (%) 55 (33.7%) 26 (16.1%)
Other, n (%) 25 (14.9%) 33 (20.5%)
Preoperative LiMAx, mg/kg/h, median (IQR) 346 (269–444) 323 (239–405) 0.037
Surgery <0.0001c
None, n (%) 10 (6.0%) 49 (30.4%)
Only laparotomy, n (%) 19 (11.8%) 23 (14.3%)
Minor resection, n (%) 16 (9.5%) 26 (16.1%)
Hemi-hepatectomy, n (%) 79 (47.0%) 48 (29.8%)
Trisectorectomy 44 (26.2%) 15 (9.3%)
Mortality (intra-hospital after hepatectomy), n (%) 13 (9.4%) 3 (3.4%) 0.019d
Statistical analysis by at-test for independent samples, bchi-squared test, cMann–Whitney U-test and dFisher's exact test
IQR, interquartile range
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tive mortality after hepatectomy was only 3.4% and thus lower
than in the prior period in which LiMAx readouts were blinded (P
= 0.019) (Table 1).
Discussion
The lack of an accurate preoperative test with which to predict
postoperative outcome before hepatectomy was the motivation
for the development of a novel test protocol for a bedside
breath test with 13C-methacetin.15 Fundamental methodological
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Figure 2 Development of liver function after hepatectomy, showing
the perioperative course of liver function capacity, as determined by
the LiMAx test. The patients were divided into surviving and
deceased groups. Median values with error bars represent 75% and
25% quartiles. LiMAx readouts were compared using the Mann–
Whitney U-test. Data for the following tests were available:
Day -1 1 2 3 5 10
Deceased patients (n = 13) 13 9 7 11 8 8
Survivors (n = 126) 126 111 58 99 97 93
Table 2 Postoperative LiMAx values and clinical outcomes in 139 patients
<80 mg/kg/h 80–100 mg/kg/h 100–150 mg/kg/h >150 mg/kg/h P-value
Patients, n (%) 21 (15.1%) 19 (13.7%) 42 (30.2%) 57 (41.1%)
Intensive care, days, median (IQR) 12 (4–26) 3 (1–16) 2 (1–4) 1 (1–3) <0.0001a
Hospitalization, days, median (IQR) 25 (17–35) 20 (15–39) 16 (13–41) 14 (10–26) 0.056a
In-hospital mortality, n (%) 8 (38.1%) 2 (10.5%) 1 (2.4%) 0 <0.0001b
Patients receiving hepatectomy (n = 139) were classified into four categories by LiMAx readouts on postoperative day 1. This classification was
compared with length of stay (in the intensive care unit and general ward) and mortality during the hospital stay
Statistical analysis by aKruskal–Wallis test, bchi-squared test
IQR, interquartile range
Figure 1 Preoperative LiMAx evaluation. The box plots present
LiMAx values determined during preoperative evaluation, divided
into resected patients and patients refused surgery. Different results
were obtained during (A) the initial clinical studies and (B) the later
routine application of the LiMAx test. Boxes indicate medians with
interquartile ranges; bars represent minimum and maximum values
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considerations and the need to adapt the test to the practical needs
of surgical management led to the design of a completely new test
protocol with i.v. substrate administration, real-time online
assessment and an automatic kinetic analysis with prompt test
readouts. These specifications were seen as preconditions for
achieving reliable test results with clinical meaning, as well as
ensuring a high clinical utility of the test system, so that any
medical specialist can easily perform the test. The LiMAx test
would seem to meet these criteria.
Previous work by the authors has shown the LiMAx to be an
independent predictor of PLF and mortality.15 The evaluation of
diagnostic power consequently revealed a high individual validity,
as shown during area under receiver operating characteristic curve
(AUROC) analysis.15 The critical point for PLF was identified as a
postoperative LiMAx value of <85 mg/kg/h. In addition, poor but
uncritical LiMAx values in the initial postoperative phase have
been associated with secondary severe complications, such as
postoperative bleeding, pleural effusions or septic infections.15
Normal values were retrieved from a group of healthy volunteers
and determined as LiMAx > 315 mg/kg/h.15
The current study shows that, even without the benefit of
LiMAx test results, surgeons are more likely to decline patients
with poorer preoperative hepatic function. However, by contrast
with this group-based strategy, valid individual prediction could
be significantly improved with the new LiMAx test, allowing indi-
vidual patient management according to the developed algorithm
(Fig. 3). Another important advantage is that it may allow sur-
geons to offer surgery to patients they might previously have
declined. Two patients within the Routine group had previously
been declined surgery because of the extent of their cirrhosis.
LiMAx values were obtained (392 mg/kg/h and 511 mg/kg/h) and
both patients subsequently underwent major hepatectomy (right
hemi-hepatectomy and trisectorectomy) and were discharged
after 21 and 17 days, respectively.
Although preoperative hepatic function is important, residual
function and its ability to regenerate are also crucial to short-term
outcomes, as shown in the current study (Table 2). However, it is
also important to consider intraoperative factors such as blood
loss and warm ischaemic time, which may have deleterious effects
on postoperative function. The LiMAx can assist in identifying
these patients early in the postoperative period.15
Since January 2008, the LiMAx test has become available in
routine preoperative evaluation. Clearly, the proportional increase
in the number of patients with hepatocellular carcinoma (HCC)
and the number of patients for whom surgery was refused indicate
that surgeons have chosen to use it selectively (Table 1). Although
the Routine group represents a potentially higher-risk group, its
mortality rate was significantly lower than that seen in the Study
group (Table 1). However, given the nature of the study, this dif-
ference should be interpreted with caution. A complex decision
tree algorithm for preoperative evaluation was developed during
the application of the LiMAx test and enhanced with increasing
clinical experience. The flowchart in Fig. 3 presents the current
decision tree used for patients with malignant hepatic tumours in
our department. First of all, the risk for any pre-existing hepatic
impairment must be evaluated. This includes the anamnesis of all
relevant risk factors for liver disease, such as chronic hepatitis,
alcohol abuse, exposure to toxins (environmental or medical, such
as chemotherapy), genetic disorders, or obstructive jaundice, as
well as the analysis of standard blood parameters in clinical chem-
istry. If hepatic impairment is unlikely, small resections of up to
two liver segments can be performed without further diagnostic
workup. If hepatic injury is suspected or larger resections need to
be performed, a preoperative assessment of liver function with the
LiMAx test is recommended. Normal liver function (LiMAx >
315 mg/kg/h) allows the resection of up to four liver segments
without further consideration. By contrast, patients with strongly
impaired liver function (LiMAx < 140 mg/kg/h, representing sig-
nificant hepatic injury) must be refused surgery as they are prone
to developing PLF after minor liver resection.
However, the most challenging decisions pertain to patients
with intermediate liver function (140–315 mg/kg/h, representing
limited hepatic impairment) or a planned resection of more than
four segments. In the future preoperative volume and function
analysis might effectively augment therapeutic decisions by pre-
dicting residual liver function after surgery, as demonstrated in
Fig. 4. If this is so, procedures with expected residual LiMAx
values of <80 mg/kg/h should not be performed according to the
results of the current study (38.1% postoperative mortality). Pro-
cedures with expected residual LiMAx values of 80–100 mg/kg/h
are still critical (10.5% postoperative mortality) and thus alterna-
tive therapies or additional preoperative procedures should be
considered. These might include selective portal vein emboliza-
tion, which could enlarge residual liver volume,16 or neo-adjuvant
chemotherapy, which could downstage tumours and thus allow
smaller resection volumes.17 In addition, intraoperative proce-
dures such as in- and outflow occlusion (e.g. Pringle manoeuvre)
should be strictly limited in these patients in order to minimize
additional hepatocellular injury. Procedures with expected
residual LiMAx values of >100 mg/kg/h (1.0% postoperative mor-
tality) are feasible with a high degree of safety (Table 2, Fig. 3).
Clearly, these cut-off values need to be further validated with
prospective studies correlating predicted postoperative volume
and function with actual postoperative values.
In the future, combined volume and function analysis might be
applied in every clinical situation and aetiology, and thus surgical
procedures tailored to optimize residual function. However, at
present it is important to remember that neither the LiMAx test
nor volume planning can currently predict the effect of intraop-
erative events such as hepatic ischaemia (Pringle manoeuvre) or
blood loss. Therefore, it may be sensible to consider retaining a
‘margin for error’ for patients in whom a significant hepatic event
is anticipated. Moreover, residual liver function is an essential but
not unique limitation of hepatectomy. Therapeutic decisions
must include multiple diagnostic parameters and clinical factors.
Along with the expected residual function, pre-existing liver dis-
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eases, such as liver fibrosis, cholestasis or hepatitis, intraoperative
surgical procedures and, of course, tumour stage and the general
condition of the patient must be taken into account. Further
methodical considerations and clinical studies will aim to opti-
mize the test reliability and individual accuracy, particularly in
relation to potential parameters that might bias the individual test
result, such as haemodialysis, smoking and nutrition, as well as
genetic variations or visceral haemodynamics. Further, it would
seem to be appropriate to evaluate the effects of neoadjuvant
chemotherapy or preoperative portal-venous embolization in
order to provide the surgeon with important information regard-
ing surgical resection following these procedures.1
In conclusion, the LiMAx decision tree algorithm for hepatec-
tomy might significantly improve preoperative evaluation and
postoperative outcome in liver surgery.
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